Edison Scientific is threading its Kosmos AI platform through Population Health Partners' existing company-creation engine, aiming to speed up everything from spotting disease targets to filing regulatory documents for new biotechs that chase conditions affecting millions.
go @SGRodriques !!
AI scientist company Edison Scientific tapped by team behind Metsera to create new biotechs https://www.statnews.com/2026/06/29/edison-scientific-population-health-partners-deal-to-create-new-biotechs/
The tool will sit inside ideation, data review, and even regulatory writing steps, extending the same system Edison already placed at Incyte into a setting built for spinning out fresh companies rather than supporting one large pipeline.
Cardiovascular, inflammatory lung, and gastrointestinal programs lead the list with one advanced asset already in play, yet any concrete timeline, new company names, or confirmed move into obesity still sit outside the current announcement.
Users congratulated teams on Edison Partners' deals to deploy Kosmos AI for biotech creation and drug discovery, calling the work super cool and needed for rare-disease labs.
No Digg Deeper questions have been answered for this story yet.
#1461At Edison, we are on a mission to leverage AI to prevent or cure all diseases.
Today, we are announcing a critical step: our first partnership using our AI scientist, Kosmos, to launch new biotech companies.
Many of the most transformative new medicines begin life in biotech companies rather than big pharmas.
We are partnering with Population Health Partners (PHP) to deploy Kosmos across their company creation pipeline. Kosmos will assist in the creation of PHP’s companies, allowing us to bring more medicines to patients.
PHP has an outstanding track record of incubating successful biotech companies like @MetseraInc (acquired by @pfizer in a $10B deal), and The Medicines Company (acquired by @Novartis for $9.7B), to name just two. With PHP, we will focus on biotechs treating population-scale diseases like cardiovascular disease and obesity.
If we can scale up the process of launching Metsera-style companies, we have an opportunity to transform medicine in the coming years.
If you want to work on using AI to accelerate the discovery of new medicines and scale up the creation of new biotech companies, get in touch.
More on our collaboration here: https://edisonscientific.com/news/creating-novel-biotechs-focused-on-population-scale-diseases-announcing-our-partnership-with-population-health-partners
At Edison, we are on a mission to leverage AI to prevent or cure all diseases.
Today, we are announcing a critical step: our first partnership using our AI scientist, Kosmos, to launch new biotech companies.
Many of the most transformative new medicines begin life in biotech companies rather than big pharmas.
We are partnering with Population Health Partners (PHP) to deploy Kosmos across their company creation pipeline. Kosmos will assist in the creation of PHP’s companies, allowing us to bring more medicines to patients.
PHP has an outstanding track record of incubating successful biotech companies like @MetseraInc (acquired by @pfizer in a $10B deal), and The Medicines Company (acquired by @Novartis for $9.7B), to name just two. With PHP, we will focus on biotechs treating population-scale diseases like cardiovascular disease and obesity.
If we can scale up the process of launching Metsera-style companies, we have an opportunity to transform medicine in the coming years.
This is a really nice partnership that allows to scale-out our impact across biotechs. Excited to be working with the PHP team, which is amazing
At Edison, we are on a mission to leverage AI to prevent or cure all diseases.
Today, we are announcing a critical step: our first partnership using our AI scientist, Kosmos, to launch new biotech companies.
Many of the most transformative new medicines begin life in biotech companies rather than big pharmas.
We are partnering with Population Health Partners (PHP) to deploy Kosmos across their company creation pipeline. Kosmos will assist in the creation of PHP’s companies, allowing us to bring more medicines to patients.
PHP has an outstanding track record of incubating successful biotech companies like @MetseraInc (acquired by @pfizer in a $10B deal), and The Medicines Company (acquired by @Novartis for $9.7B), to name just two. With PHP, we will focus on biotechs treating population-scale diseases like cardiovascular disease and obesity.
If we can scale up the process of launching Metsera-style companies, we have an opportunity to transform medicine in the coming years.
@celinehalioua Thanks @celinehalioua!
go @SGRodriques !!
@SGRodriques @srikosuri Congrats Sam and team!!
@SGRodriques Super cool, having spent last 4 years building rare disease labs for families and patients, what your building is needed!! Would love to learn more.
@SGRodriques Yeah I’d be down.
@SGRodriques really interested in this use-case
@SGRodriques I would like to contribute on Alzheimer, microvascular angina and cardiovascular diseases.